Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors
CompanyDeals

Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors

NHSA Releases Draft Regulations to Tighten Medical Insurance Funds Oversight
Policy / Regulatory

NHSA Releases Draft Regulations to Tighten Medical Insurance Funds Oversight

Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
CompanyDeals

Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies

Junshi Biosciences' JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial
CompanyDrug

Junshi Biosciences’ JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial

Hengrui’s RSS0393 PDE4 Inhibitor Approved for Atopic Dermatitis Clinical Trial
CompanyDrug

Hengrui’s RSS0393 PDE4 Inhibitor Approved for Atopic Dermatitis Clinical Trial

Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH
CompanyDrug

Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH

Innovent’s Xinbimin IGF‑1R Antibody Approved in Macau
CompanyDrug

Innovent’s Xinbimin IGF‑1R Antibody Approved in Macau

TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
CompanyDrug

TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC

Simcere Launches Quviviq, New Insomnia Therapy in China
CompanyDrug

Simcere Launches Quviviq, New Insomnia Therapy in China

Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor
CompanyDeals

Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor

Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
CompanyDeals

Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus

Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
CompanyDrug

Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy